미국의 당뇨병성 족궤양 치료 시장 규모, 점유율, 동향 분석 리포트 : 치료별, 궤양 유형별, 최종 용도별, 부문별 예측(2024-2030년)

U.S. Diabetic Foot Ulcer Treatment Market Growth & Trends:

The U.S. diabetic foot ulcer treatment market size is anticipated to reach USD 2.47 billion by 2030, expanding at a CAGR of 5.25% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors contributing to market growth include the increasing occurrence of diabetes nationwide, an aging population, advancements in treatment technology, rising research and development efforts, and shifts in lifestyle patterns. For instance, according to the Population Reference Bureau's projections, the population of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by the year 2050, reflecting a 47% increase.

The prevalence of diabetes in the U.S. plays a significant role in market expansion, as diabetic foot ulcers are a common complication of the disease. For instance, according to the International Diabetes Federation, in 2021 there were about 32.21 million diabetes patients aged 20-79 years in the U.S. which are further expected to increase to 36.28 million by 2045. Furthermore, the advancements in medical technology and treatment modalities contribute to the growth of the market. Innovations such as advanced wound care products, bioengineered tissues, and regenerative medicine techniques offer more effective and efficient solutions for diabetic foot ulcer management.

Furthermore, the increasing awareness among healthcare providers and patients of the importance of early detection and proper treatment of diabetic foot ulcers is driving the market growth. Both healthcare professionals and patients understand the necessity of careful foot care and regular screenings to catch diabetic foot ulcers early. This heightened awareness encourages a proactive approach to managing complications of diabetes, leading to better outcomes for patients and fewer severe ulcers. Additionally, ongoing research and development efforts are essential in advancing treatment options and technologies for managing diabetic foot ulcers. These continued efforts result in innovative solutions, such as new therapies, diagnostic tools, and preventive measures, which expand the options available to healthcare providers.

Presence of major market participants and various initiatives undertaken by them to stay competitive in the market such as product approval, product launch, partnership, merger and acquisition, expansion, etc. are expected to contribute to the overall market growth. For instance, in April 2024, Molnlycke Health Care has announced its plans to acquire P.G.F. Industry Solutions GmbH, an Austrian company known for producing Granudacyn, a line of wound cleansing and moisturizing products.

U.S. Diabetic Foot Ulcer Treatment Market Report Highlights:

• Based on treatment, the biologics segment dominated the market by capturing a revenue share of more than 30% in 2023
• The therapy devices segment is anticipated to grow at the fastest CAGR during the forecast period
• Based on ulcer type, the neuro-ischemic ulcers segment held the largest market share in 2023
• The Ischemic ulcers segment is expected to grow at a fastest rate from 2024 to 2030
• Based on end-use, hospitals and clinics led the market in 2023
• North America dominated the market in 2023

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. Ulcer Type
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment outlook
  • 2.2.2. Ulcer type outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Diabetic Foot Ulcer Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of diabetes
    • 3.2.1.2. Aging population
    • 3.2.1.3. Advancements in treatment technology
    • 3.2.1.4. Lifestyle changes
    • 3.2.1.5. Growing R&D activities
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
• 3.3. U.S. Diabetic Foot Ulcer Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Diabetic Foot Ulcer Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global U.S. Diabetic Foot Ulcer Treatment Market Movement Analysis
• 4.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Wound Care Dressings
  • 4.4.1. Wound care dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.1. Alginate dressings
    • 4.4.1.1.1. Alginate dressing market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.2. Hydrofiber dressings
    • 4.4.1.2.1. Hydrofiber dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.3. Foam dressings
    • 4.4.1.3.1. Foam dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.4. Film dressing
    • 4.4.1.4.1. Film dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.5. Hydrocolloid dressings
    • 4.4.1.5.1. Hydrocolloid dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.6. Surgical Dressings
    • 4.4.1.6.1. Surgical dressings market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.1.7. Hydrogel dressings
    • 4.4.1.7.1. Hydrogel dressings market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Biologics
  • 4.5.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.1.1. Growth factors
    • 4.5.1.1.1. Growth factors market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.1.2. Skin grafts
    • 4.5.1.2.1. Skin grafts market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Therapy devices
  • 4.6.1. Therapy devices market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.1.1. Negative pressure wound therapy
    • 4.6.1.1.1. Negative pressure wound therapy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.1.2. Ultrasound therapy
    • 4.6.1.2.1. Ultrasound therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Antibiotic medicine
  • 4.7.1. Antibiotic medicine market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Diabetic Foot Ulcer Treatment Market: Ulcer Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global U.S. Diabetic Foot Ulcer Treatment Ulcer Type Market Movement Analysis
• 5.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by Ulcer Type, 2018 to 2030 (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030
• 5.5. Neuropathic Ulcers
  • 5.5.1. Neuropathic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Ischemic Ulcers
  • 5.6.1. Ischemic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Neuro-ischemic Ulcers
  • 5.7.1. Neuro-ischemic ulcers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Diabetic Foot Ulcer Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global U.S. Diabetic Foot Ulcer Treatment End Use Market Movement Analysis
• 6.3. Global U.S. Diabetic Foot Ulcer Treatment Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgery Center
  • 6.5.1. Ambulatory surgery center market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Homecare
  • 6.6.1. Homecare market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Key company market share analysis, 2023
• 7.4. Company Position Analysis
• 7.5. Company Categorization (Emerging Players, Innovators and Leaders
• 7.6. Company Profiles
  • 7.6.1. ConvaTec, Group Plc
    • 7.6.1.1. Company overview
    • 7.6.1.2. Financial performance
    • 7.6.1.3. Product benchmarking
    • 7.6.1.4. Strategic initiatives
  • 7.6.2. 3M Health Care
    • 7.6.2.1. Company overview
    • 7.6.2.2. Financial performance
    • 7.6.2.3. Product benchmarking
    • 7.6.2.4. Strategic initiatives
  • 7.6.3. Coloplast Corp.
    • 7.6.3.1. Company overview
    • 7.6.3.2. Financial performance
    • 7.6.3.3. Product benchmarking
    • 7.6.3.4. Strategic initiatives
  • 7.6.4. Smith & Nephew Plc
    • 7.6.4.1. Company overview
    • 7.6.4.2. Financial performance
    • 7.6.4.3. Product benchmarking
    • 7.6.4.4. Strategic initiatives
  • 7.6.5. B Braun Melsungen AG
    • 7.6.5.1. Company overview
    • 7.6.5.2. Financial performance
    • 7.6.5.3. Product benchmarking
    • 7.6.5.4. Strategic initiatives
  • 7.6.6. Medline Industries, LP.
    • 7.6.6.1. Company overview
    • 7.6.6.2. Financial performance
    • 7.6.6.3. Product benchmarking
    • 7.6.6.4. Strategic initiatives
  • 7.6.7. Molnlycke Health Care AB
    • 7.6.7.1. Company overview
    • 7.6.7.2. Financial performance
    • 7.6.7.3. Product benchmarking
    • 7.6.7.4. Strategic initiatives
  • 7.6.8. Medtronic Plc
    • 7.6.8.1. Company overview
    • 7.6.8.2. Financial performance
    • 7.6.8.3. Product benchmarking
    • 7.6.8.4. Strategic initiatives